GoAI
Get started
Altimmune, Inc. logo

Altimmune, Inc.

ALT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.11

+$0.16 · +5.42%

Aug 21, 4:00 PM ET

Pre-market

$3.23

+$0.12 · +3.86%

Aug 24, 5:00 AM ET

ALT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

42

Fair Value

Momentum

34

Weakening

Sentiment

59

Mixed

Risk resilience

46

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jerome Benedict Durso
Listed since
May 26, 2017
Employees
57

Market position

Day range

Current $3.11

52-week range

Current $3.11

Open
$2.97
Previous close
$2.95
Volume
6.16M
1.37× average
Average volume
4.51M
Average daily volume
Market cap
604.81M USD
Beta
0.17
Market reference 1
50-day average
$2.929
+6.18% above average
200-day average
$3.6903
-15.72% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.99×
P/B (TTM)
1.22×
P/S (TTM)
19,510.13×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-48306.45%
Operating margin
-323306.45%
Net margin
-296000.00%

Financial health

Debt / equity
0.08×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends193518%-64437%-322393%-580349%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -2197.60%Operating margin, FY2022: 129029.41%Operating margin, FY2023: -22518.54%Operating margin, FY2024: -515860.00%Operating margin, FY2025: -230460.98%Net margin, FY2021: -2201.59%Net margin, FY2022: 124577.94%Net margin, FY2023: -20762.21%Net margin, FY2024: -475295.00%Net margin, FY2025: -214860.98%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -2197.60%. Operating margin FY2022 129029.41%. Operating margin FY2023 -22518.54%. Operating margin FY2024 -515860.00%. Operating margin FY2025 -230460.98%. Net margin FY2021 -2201.59%. Net margin FY2022 124577.94%. Net margin FY2023 -20762.21%. Net margin FY2024 -475295.00%. Net margin FY2025 -214860.98%.

Income trends

Revenue

41K USD+105.00%

Operating income

−94.49M USD+8.42%

Net income

−88.09M USD+7.33%
Income trends across reported periods15.17M USD−27.86M USD−70.9M USD−113.93M USDRevenue, FY2021: 4.41M USDRevenue, FY2022: −68K USDRevenue, FY2023: 426K USDRevenue, FY2024: 20K USDRevenue, FY2025: 41K USDOperating income, FY2021: −96.91M USDOperating income, FY2022: −87.74M USDOperating income, FY2023: −95.93M USDOperating income, FY2024: −103.17M USDOperating income, FY2025: −94.49M USDNet income, FY2021: −97.09M USDNet income, FY2022: −84.71M USDNet income, FY2023: −88.45M USDNet income, FY2024: −95.06M USDNet income, FY2025: −88.09M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.41M USD. Revenue FY2022 −68K USD. Revenue FY2023 426K USD. Revenue FY2024 20K USD. Revenue FY2025 41K USD. Operating income FY2021 −96.91M USD. Operating income FY2022 −87.74M USD. Operating income FY2023 −95.93M USD. Operating income FY2024 −103.17M USD. Operating income FY2025 −94.49M USD. Net income FY2021 −97.09M USD. Net income FY2022 −84.71M USD. Net income FY2023 −88.45M USD. Net income FY2024 −95.06M USD. Net income FY2025 −88.09M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue41K USD20K USD426K USD−68K USD4.41M USD
Gross profit41K USD20K USD426K USD−68K USD4.41M USD
Research and development66.43M USD82.23M USD65.8M USD70.54M USD74.54M USD
Selling, general, and administrative28.1M USD20.97M USD18.14M USD17.13M USD15.41M USD
Operating expenses94.53M USD103.19M USD96.36M USD87.67M USD101.32M USD
Interest income7.54M USD8.07M USD7.35M USD2.87M USD203K USD
Interest expense1.64M USD9K USD35K USD8K USD5K USD
Depreciation and amortization112K USD238K USD477K USD493K USD551K USD
Operating income−94.49M USD−103.17M USD−95.93M USD−87.74M USD−96.91M USD
Net income−88.09M USD−95.06M USD−88.45M USD−84.71M USD−97.09M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+12.75%
11 comparable reports
Latest EPS result
-0.12
Estimate -0.14 · Beat by 11.44%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.1-0.2-0.29-0.39Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.33, estimate -0.34, surprise +2.94%, Beat. Q2 2025, reported May 13, 2025: actual -0.26, estimate -0.35, surprise +25.71%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.27, estimate -0.32, surprise +15.62%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.21, estimate -0.29, surprise +27.59%, Beat. Q1 2026, reported Mar 5, 2026: actual -0.27, estimate -0.25, surprise -8.00%, Miss. Q2 2026, reported May 13, 2026: actual -0.18, estimate -0.25, surprise +28.00%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.12, estimate -0.136, surprise +11.44%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.14, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates28.04K18.85K9.66K472.6Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 5K USD, estimate 1K USD, surprise +400.00%, Beat. Q2 2025, reported May 13, 2025: actual 5K USD, estimate 560 USD, surprise +792.86%, Beat. Q3 2025, reported Aug 12, 2025: actual 5K USD, estimate 1.43K USD, surprise +249.90%, Beat. Q4 2025, reported Nov 6, 2025: actual 5K USD, estimate 560 USD, surprise +792.86%, Beat. Q1 2026, reported Mar 5, 2026: actual 26K USD, estimate 556 USD, surprise +4576.26%, Beat. Q2 2026, reported May 13, 2026: actual —, estimate 1.43K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 11, 2026: actual —, estimate 2K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.75K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$6.25

100.96% upside
Past 12 months12-month forecastHigh $10.00Average $6.25Low $2.50

Rating distribution

15 ratings
Strong buy00%
Buy1280%
Hold320%
Sell00%
Strong sell00%

Corporate actions

Corporate action history

Dividend

Ex-dividend Feb 6, 2017

$291

Monthly

Record Jan 24, 2017

Dividend

Ex-dividend Jan 20, 2017

$291

Monthly

Record Jan 24, 2017 · Payment Feb 3, 2017

ALT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ALT

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
25.07M
Weight
0.22%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
16.33M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
14.99M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.36M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
5.48M
Weight
0.04%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
4.08M
Weight
0.06%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
4.02M
Weight
0.04%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.17M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research ALT

research.disclaimer